Abstract: This disclosure contemplates tagging cells or vesicles with agents using a tension activated device. In certain embodiments, a solid surface is conjugated to a double stranded nucleic acid complex wherein a first strand is conjugated to the surface containing a ligand, and a second strand is conjugated to a lipophilic agent. In certain embodiments, the first and/or second strand is conjugated to a label, e.g., fluorescent dye. In certain embodiments, a cell or vesicle comprising a receptor that binds to the ligand provides tension on the double stranded complex to denature the strands resulting the cell membrane associating with or incorporating the lipid conjugated strand.

Abstract: This disclosure contemplates methods of detecting, measuring, and/or quantifying a tensional force on cells that express an antigen. In certain embodiments, this disclosure relates to methods and devices disclosed herein used to determine or monitor whether a cancer therapy or other immunotherapy is appropriate for a specific patient. In certain embodiments, the therapy is administering blinatumomab or other bispecific engager to a patient.

Abstract: This disclosure relates to phosphate membrane nanodiscs covalently modified with therapeutic agents such as antisense oligonucleotides or other nucleobase polymers and medical uses related thereto. In certain embodiments, the phosphate membrane nanodiscs comprise a phospholipid having a thiol group used for conjugation to agents such as oligonucleotides or other nucleobases polymers having a thiol reactive group. In certain embodiment, the phosphate membrane nanodiscs comprise a stabilizing peptide having a thiol group used for further conjugation to therapeutic agents.

Abstract: This disclosure relates to heteromultivalent nucleic acid-functionalized surfaces, such as particles, and uses in optimizing hybridization specificity for targets containing one, two, or more mutations. In certain embodiments, heteromultivalent hybridization enables fine-tuned specificity for a single SNP and dramatic enhancements in specificity for two non-proximal SNPs empowered by cooperative binding. In certain embodiments, use of specified oligo lengths, spacer lengths, and binding orientation are contemplated. In certain embodiments, this disclosure provides for methods of discrimination between heterozygous cis and trans mutations and between different strains of a virus, e.g., the SARS-CoV-2 virus.

Abstract: This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.

Abstract: This disclosure relates to sensing the movement of DNA rolling motors comprising microparticles or rods on transduction material in the presence of viruses, microbes, or other analytes for diagnostic testing. In certain embodiments, the presence of viral particles, other target microbial biomolecules, or analytes stall the motor by specifically binding to aptamers crosslinking the analytes to the particles, rods, or surface of the transduction material. It is contemplated that microparticles or other rolling motors move along a surface whereby an aptamer targets an analyte, e.g., viral SARS-CoV-2, and acts to inhibit, reduce, or restrict the speed, acceleration, or area of movement on the surface indicating the presence of the analyte in the sample.

Abstract: This disclosure relates to non-naturally occurring light reflecting or color changing materials comprising a segmented array of flexible polymers, wherein the segmented array of flexible polymers comprise photonic crystal lattices embedded therein, wherein the segmented array of flexible polymers are themselves embedded within an elastic supporting polymer that maintains a near constant size during chromatic shifting of the photonic crystal lattices.

Abstract: This disclosure relates to conditional double stranded antisense oligonucleotides and uses in managing diseases and conditions. In certain embodiments, the conditional double stranded antisense oligonucleotides are non-naturally occurring double stranded nucleobase polymer complexes comprising a first strand and a second strand, wherein the first strand is an antisense oligonucleotide connected to a segment that is partially identical to cell specific RNA, e.g., microRNA, and the second strand is a locking strand configured to release the first strand when in the presence of the cells specific RNA; thus, releasing the antisense oligonucleotide in a manner limited to cells that express a specific RNA.

Abstract: This disclosure relates to spherical nucleic acids comprising a group of nucleic acids that hybridize separate segments of a target nucleic acid for therapeutic and diagnostic applications. In certain embodiments, this disclosure relates to patterning spherical nucleic acids in tandem for hetero-multivalent hybridization to segments of a target nucleic acid.

Abstract: This disclosure relates DNA based movement of objects. In certain embodiments, particles, pairs of particles, or rods are conjugated with single stranded DNA that hybridizes to a single stranded RNA that is conjugated to a substrate. When the DNA particle, pair of particles, or rod interacts with the surface RNA in the presence of an endonuclease, such as RNase H and the DNA hybridizes to the RNA, then the particle, pair of particles, or rod moves along the surface. The complementarity of the DNA and RNA affect the velocity.

Abstract: This disclosure relates to non-naturally occurring light reflecting or color changing materials comprising a segmented array of flexible polymers, wherein the segmented array of flexible polymers comprise photonic crystal lattices embedded therein, wherein the segmented array of flexible polymers are themselves embedded within an elastic supporting polymer that maintains a near constant size during chromatic shifting of the photonic crystal lattices.

Abstract: This disclosure relates to compositions comprising particles conjugated to one or more catalytically cleaving nucleic acids and optionally an RNA ligating enzyme. In certain embodiments, particles reported herein are used for splicing nucleic acid sequences.

Abstract: This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.

Abstract: This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.

Abstract: In certain embodiments, this disclosure relates to devices and methods for imaging transient mechanical events in cells. In certain embodiments, this disclosure contemplates devices comprising receptors, cells or cell membranes comprising receptors, a molecular beacon as a linker between a solid surface and a ligand, and a locking oligonucleotide that selectively binds a portion of the hairpin turn and stem of the molecular beacon when the beacon is mechanically melted with piconewton forces. In certain embodiments, this disclosure relates to methods of locking, unlocking, and imaging cellular events using labeled locking and unlocking oligonucleotides disclosed herein.

Abstract: This disclosure related to methods of detecting mechanical forces required to separate ligand and receptor interactions. In certain embodiments, this disclosure relates to methods of detecting mechanical forces between a ligand and receptor, where the ligand is immobilized on a surface using weaker forces. Ligand-receptor forces lead to dissociation of the ligand that can be detected and amplified. In certain embodiments, the disclosure relates to methods of detecting ligand and receptor interactions comprising linking a ligand to one of two binding partners, wherein the binding partners have attracting forces that are less than the forces between the ligand and a receptor of the ligand such that when the ligand binds the receptor, the binding partners will separate. Separation of the binding partners can be detected.

Abstract: This disclosure relates DNA based movement of objects. In certain embodiments, particles, pairs of particles, or rods are conjugated with single stranded DNA that hybridizes to a single stranded RNA that is conjugated to a substrate. When the DNA particle, pair of particles, or rod interacts with the surface RNA in the presence of an endonuclease, such as RNase H and the DNA hybridizes to the RNA, then the particle, pair of particles, or rod moves along the surface. The complementarity of the DNA and RNA affect the velocity.

Abstract: This disclosure relates DNA based movement of objects. In certain embodiments, particles, pairs of particles, or a rods are conjugated with single stranded DNA that hybridizes to a single stranded RNA that is conjugated to a substrate. When the DNA particle, pair of particles, or rod interacts with the surface RNA in the presence of an endonuclease, such as RNase H and the DNA hybridizes to the RNA, then the particle, pair of particle, or rod moves along the surface. The complementarity of the DNA and RNA affect the velocity.

Abstract: This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.

Abstract: This disclosure relates to compositions comprising particles conjugated to one or more catalytically cleaving nucleic acids and optionally an RNA ligating enzyme. In certain embodiments, particles reported herein are used for splicing nucleic acid sequences.